Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
德琪(浙江)医药科技有限公司 Deqi (zhejiang) Pharmaceutical Technology Co. LTD
{{company.company_channel.channel_name}}
Media Room
Latest
Photos
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Follow :
X
Company Profile
Media Room
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.title}}
loading
The End
Network Errors Please Retry
{{selectname}}
{{showName}}
{{selectall}}
{{option}}
Antengene to Participate in Three Upcoming Investor Conferences in May/June
2022-05-06 08:30
Antengene Announces Latest Clinical Trial Data of ATG-008 (onatasertib) to be presented in the upcoming 2022 American Society of Clinical Oncology Annual Meeting
2022-04-29 22:30
Antengene Announces Submission to the Human Research Ethics Committee in Australia for a Phase I Trial of ATG-018
2022-04-27 08:30
Antengene Announces Publication of Five Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting
2022-04-11 08:30
Antengene's Pivotal "MARCH" Study to Evaluate Selinexor (ATG-010) in Relapsed or Refractory Multiple Myeloma Published in BMC Medicine
2022-04-06 20:03
Antengene Announces IND Approval in China for a Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes
2022-03-30 09:00
Antengene Announces 2021 Full Year Financial Results and Provides Corporate Updates
2022-03-18 22:12
Antengene Announces IND Approval in China for the Phase I Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma
2022-03-10 08:52
Antengene Announces Five Upcoming Presentations at the 2022 American Association for Cancer Research Annual Meeting
2022-03-09 20:00
Antengene Announces XPOVIO® Approved by the TGA in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Triple Class-Refractory Multiple Myeloma
2022-03-09 19:08
Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications
2022-03-02 08:47
Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037
2022-02-07 08:30
Antengene to Present at the 40th Annual J.P. Morgan Healthcare Conference
2022-01-05 12:50
Antengene Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors
2021-12-30 09:51
First Patient Dosed in Australia in ATG-101 First-in-Human Trial
2021-12-20 11:01
First Patient Dosed in Australia in ATG-101 First-in-Human Trial
2021-12-20 10:56
Antengene Announces NDA Approval by NMPA for XPOVIO®, China's First XPO1 inhibitor, for the Treatment of Adults with Relapsed or Refractory Multiple Myeloma
2021-12-17 22:27
Antengene and XtalPi Announce AI-Driven R&D Collaboration
2021-12-16 16:30
Antengene Presents Results of Phase 1b TOUCH Trial of Selinexor for the Treatment of T and NK-Cell Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting
2021-12-14 18:00
Antengene Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate ATG-017 in Combination with Opdivo® (nivolumab) in Advanced Solid Tumors
2021-12-13 08:30
1
2
3
4
5
6
8